Fount of Information

AcroBiosystems社 How do Mu (B.1.621) & C.1.2 variants affect the war against SARS-CoV-2?

この製品に関するご意見・ご照会・お問合せはこちら

Comprehensive_ADC_target_1.png

 Products

Support

Scientific Talk

COVID-19 R&D

About Us

  

 How do Mu (B.1.621) & C.1.2 variants affect the war against SARS-CoV-2?

   


  

In August 2021, the new SARS-CoV-2 VOI variant Mu (PANGO lineage: B.1.621) sparked a wave of attention for its potential risk as a highly transmissible and immune-resistant strain. Since its first identification in January 2021 in Columbia, the variant has been responsible for most COVID-19 cases circulating in the country and its neighbors.

Simultaneously, on the other side of the globe, a C.1.2 strain with an unprecedented set of complicated mutations on the spike protein emerged in South Africa.

 

In response to the challenges of the emerging variants, ACROBiosystems has rapidly developed the spike protein mutants of Mu (B.1.621) and C.1.2, including Spike RBD, spike NTD and full-length spike trimer with high purity and good bioactivity

 

now_in_stock.PNG

  


 

Product lists

 

Product_lists.png

 


 

Assay Data

 

  • The purity of Cat. No. SPN-C52Ha is greater than 90% with the verification of SDS-PAGE and MALS. 

   

Assay_data1.png

 

Immobilized SARS-CoV-2 Spike Trimer, His Tag (Cat. No. SPN-C52Ha) at 1 μg/mL (100 μL/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-3 ng/mL (QC tested). It can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.1-2 ng/mL (Routinely tested). 

 

Assay_data2.png

   


 


 

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。